Atai Life Sciences N.V. (ATAI)

Mar 11, 2025, 7:00 AM EDT - 6 weeks ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 27, 2025, 12:45 PM EST - 7 weeks ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 24, 2025, 4:10 PM EST - 2 months ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 7:00 AM EST - 2 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Feb 12, 2025, 10:47 PM EST - 2 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Feb 12, 2025, 4:01 PM EST - 2 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Jan 29, 2025, 11:57 AM EST - 3 months ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 10, 2025, 7:00 AM EST - 3 months ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 7 months ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 8 months ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 2:00 PM EDT - 8 months ago

Psychedelic Stock Deep Dive: Atai Life Sciences

Aug 13, 2024, 7:10 AM EDT - 9 months ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 9 months ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS CYBN MNMD

Aug 7, 2024, 7:00 AM EDT - 9 months ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 10 months ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 11 months ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 11 months ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Mar 28, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 27, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 4, 2024, 8:00 AM EST - 1 year ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Feb 28, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Jan 4, 2024, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Nov 29, 2023, 6:55 PM EST - 1 year ago

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

Nov 14, 2023, 7:03 AM EST - 1 year ago

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Oct 6, 2023, 4:05 PM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 2, 2023, 4:13 PM EDT - 1 year ago

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Sep 14, 2023, 8:02 AM EDT - 1 year ago

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 6, 2023, 4:01 PM EDT - 1 year ago

atai Life Sciences to Participate in Upcoming September Investor Conferences

Sep 1, 2023, 7:02 PM EDT - 1 year ago

Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

Aug 10, 2023, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Aug 8, 2023, 4:02 PM EDT - 1 year ago

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Jul 16, 2023, 6:00 PM EDT - 1 year ago

Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.

CMPS CYBN

Jul 13, 2023, 12:35 PM EDT - 1 year ago

Psychedelic Stocks: Don't Bet On Just 1 Company

CMPS CYBN

Jun 23, 2023, 11:14 AM EDT - 1 year ago

FDA issues guidance on psychedelic drug clinical trials

CMPS CYBN

Jun 21, 2023, 8:45 AM EDT - 2 years ago

TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.

CMPS CYBN MNMD

Jun 1, 2023, 6:59 AM EDT - 2 years ago

atai Life Sciences to Participate in Upcoming June Investor Conferences

May 11, 2023, 6:59 AM EDT - 2 years ago

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

May 2, 2023, 5:20 PM EDT - 2 years ago

atai Life Sciences to Participate in Upcoming May Investor Conference

Apr 28, 2023, 6:59 AM EDT - 2 years ago

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

Apr 13, 2023, 6:59 AM EDT - 2 years ago

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Mar 24, 2023, 6:59 AM EDT - 2 years ago

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Mar 6, 2023, 7:00 AM EST - 2 years ago

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Mar 1, 2023, 4:01 PM EST - 2 years ago

atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Jan 15, 2023, 11:45 AM EST - 2 years ago

Psychedelic Sunday: Competitive Strategies

CMPS CYBN GHRS MNMD

Jan 8, 2023, 11:30 AM EST - 2 years ago

Scrutinizing Psychedelic Stocks

CMPS CYBN MNMD

Jan 6, 2023, 11:16 AM EST - 2 years ago

The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a trial